Health Status After Switching Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers to Sacubitril-valsartan in Patients with Heart Failure with Reduced Ejection Fraction from Rural Tanzania: an Interventional Study

Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart failure is a major health problem. Before implementing ARNI in Tanzania, a study evaluating the benefit and safety of ARNI in Africans is needed. The aim of this interventional pre-post study is to evaluate the health status of symptomatic patients with heart failure with reduced ejection fraction who are under a chronic heart failure therapy, before and after switching angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) to ARNI. Participants will be recruited at the Heart and Lung Clinic of the St Francis Regional Referral Hospital in Ifakara in rural Tanzania during a study period of 30 months, including 10 months of follow-up. A total of 238 participants will be included. The investigators hypothesize that health status, expressed by the Kansas City Cardiomyopathy Questionnaire summary score and 6-minute walking test, will improve after switching from ACE-inhibitors or ARB to ARNI. In Tanzania, sacubitril/valsartan is registered under the name Uperio®.

开始日期2025-03-01

申办/合作机构

Swiss Tropical & Public Health Institute

[+1]

NCT06693674

/ Recruiting临床3期IIT

Role of Sacubitril-Valsartan for Right Ventricular Reverse Remodeling in Adults with Tetralogy of Fallot and Ebstein's Anomaly: a Randomized Controlled Pilot Clinical Trial

The purpose of this study is to compare changes in RV structure and function, biomarkers, and patient reported outcomes between TOF patients randomized to an ARNI vs placebo.

开始日期2025-02-01

申办/合作机构

Mayo Clinic

[+1]

NCT06712030

/ Not yet recruiting临床3期IIT

Effect of Pharmacological Treatment with Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction (SAVA-TTR)

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis (ATTR) and heart failure with reduced ejection fraction (LVEF ≤40%). The primary objective is to determine the impact of Sac/Vals treatment on systolic function by assessing the change in LVEF on echocardiogram at 12-month follow-up.

开始日期2025-01-01

申办/合作机构

Hospital Majadahonda SA

100 项与沙库巴曲缬沙坦钠相关的临床结果

登录后查看更多信息

100 项与沙库巴曲缬沙坦钠相关的转化医学

登录后查看更多信息

100 项与沙库巴曲缬沙坦钠相关的专利（医药）

登录后查看更多信息

522

项与沙库巴曲缬沙坦钠相关的文献（医药）

2025-03-01·BRAIN RESEARCH

Lactobacillus casei Zhang prevents hippocampal atrophy and cognitive impairment in rats with type 2 diabetes by regulating blood glucose levels

Article

作者: Liu, Sijie ; Kang, Yan ; Lin, Fuchun ; Cheng, Linlin ; Chen, Xi ; Wang, Xuxia ; Cai, Yue

PURPOSE:

Lactobacillus casei Zhang (LCZ) has health benefits, such as the ability to improve blood glucose levels in individuals with type 2 diabetes mellitus (T2DM). However, little is known about the effects of LCZ on brain structural plasticity and cognitive function in T2DM. The aims of this study were to determine whether LCZ can prevent and alleviate brain damage and memory impairment in T2DM, and to understand the mechanisms underlying the effects of LCZ in T2DM.

METHODS:

Forty-one male Sprague-Dawley rats were divided into the saline control (CON, n = 14), T2DM (n = 14) and T2DM + LCZ (n = 13) groups. Magnetic resonance imaging (MRI) was used to evaluate alterations in brain structure among these three groups. The novel object recognition and Y-maze tests were conductedto assess cognitive function. Histological and immunohistochemical analysis, including Nissl staining, Golgi-Cox staining and glial fibrillary acidic protein immunostaining, were performed to explore the pathophysiological mechanisms underlying brain structural changes.

RESULTS:

T2DM rats presented hyperglycemia, cognitive decline, hippocampal atrophy, and damage to hippocampal neurons and astrocytes. Compared with those in the T2DM groups, rats in the T2DM + LCZ group presented lower blood glucose levels, better cognitive function, a larger hippocampal volume, and more normal hippocampal neurons and astrocytes. There was no significant difference in these metrics between rats in the T2DM + LCZ and CON groups.

CONCLUSION:

Hyperglycemia-induced damage to hippocampal neurons and astrocytes may lead to hippocampal atrophy and cognitive dysfunction in T2DM. LCZ can effectively prevent this damage by regulating blood glucose levels, preventing brain atrophy and cognitive impairment in T2DM rats. These findings provide a scientific basis for the clinical application of LCZ.

2025-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Qianyang Yuyin granules alleviate hypertension-induced vascular remodeling by inhibiting the phenotypic switch of vascular smooth muscle cells

Article

作者: Zheng, Yawei ; Liu, Ming ; Fan, Yadong ; Zhang, Siqi ; Zhang, Haitao ; Sun, Zeqi ; Zheng, Ziwen ; Fang, Zhuyuan ; Jialiken, Dinala ; Zhang, Weiting ; Yan, Xiwu

ETHNOPHARMACOLOGICAL RELEVANCE:

Qianyang Yuyin granules (QYYY) have been used clinically to treat hypertension for over two decades. Previous clinical trials have shown that QYYY can improve vascular elastic function in hypertensive patients. However, the underlying pharmacological mechanism is unclear.

AIM OF THE STUDY:

To elucidate the effects and mechanisms of QYYY on vascular remodeling using a multidisciplinary approach that includes network pharmacology, proteomics, and both in vitro and in vivo experiments.

MATERIALS AND METHODS:

The main components of QYYY were identified using ultra-high-performance liquid chromatography and high-resolution mass spectrometry. Network pharmacology and molecular docking were employed to predict QYYY's primary active ingredients, potential therapeutic targets and intervention pathways in hypertensive vascular remodeling. We induced hypertension in male C57BL/6 mice by infusing angiotensin II (Ang II) via osmotic minipumps, and performed pre-treatment with QYYY or Sacubitril/valsartan (Entresto). Blood pressure was monitored in vivo, followed by the extraction of aortas to examine pathological structural changes and alterations in protein expression patterns. The expression and location of proteins involved in the HIF-1α/TWIST1/P-p65 signaling pathway were investigated, as well as markers of vascular smooth muscle cells (VSMCs) phenotypic switch. In vitro, we studied the effects of QYYY water extract on Ang II-stimulated human aortic VSMCs. We investigated whether QYYY could affect the HIF-1α/TWIST1/P-p65 signaling pathway, thereby ameliorating apoptosis, autophagy, and phenotype switch in VSMCs.

RESULTS:

We identified 62 main compounds in QYYY, combined with network pharmacology, speculated 827 potentially active substances, and explored 1021 therapeutic targets. The KEGG pathway analysis revealed that the mechanisms of action associated with QYYY therapy potentially encompass various biological processes, including metabolic pathways, TNF signaling pathways, apoptosis, Ras signaling pathways, HIF-1 signaling pathways, autophagy-animal pathways. In hypertensive mice, QYYY restored abnormally elevated blood pressure, vascular remodeling, and inflammation with a dose-response relationship while altering abnormal protein patterns. In vitro, QYYY could inhibit abnormal proliferation, migration, intracellular Ca²⁺ accumulation and cytoskeletal changes of VSMCs. It improved mitochondrial function, reduced ROS levels, stabilized membrane potential, prevented cell death, and reduced overproduction of TGF-β1, TNF-a, and IL-1β.

CONCLUSION:

QYYY may be able to inhibit the overactivation of the HIF-1α/TWIST1/P-p65 signaling pathway, improve the phenotypic switch, and balance apoptosis and autophagy in VSMCs, thereby effectively improving vascular remodeling caused by hypertension.

2025-01-01·Acta Crystallographica Section E-Crystallographic Communications

Crystal structure of luliconazole

Article

作者: Chęcińska, Lilianna ; Ben, Anna

The crystal structure of luliconazole {LCZ; C14H9Cl2N3S2; systematic name: (E)-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene](1H-imidazol-1-yl)acetonitrile} is reported. In the molecule of the title compound, the dithiolane ring adopts an envelope conformation, while the dichlorophenyl ring exhibits disorder. In the crystal packing of luliconazole, only two intermolecular C–H...N hydrogen bonds are observed. Hirshfeld surface analysis reveals that the most dominant contacts are H...N/N...H, H...Cl/Cl...H, H...H and C...H/H...C.

680

项与沙库巴曲缬沙坦钠相关的新闻（医药）

2025-01-22

·PRNewswire

Chronic Heart Failure Market to Observe Stunning Growth at a CAGR of 10% by 2034 Owing to Strong Uptake of Entresto and approved SGLT2 Inhibitors along with Emergence of New Class of Therapies | DelveInsight

Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus is expected to drive the chronic heart failure market forward. In summary, the existing blockbuster therapies such as Entresto, recently approved SGLT2 inhibitors, and Soluble guanylate cyclase (sGC) stimulators, along with emerging cell therapies, peptides, monoclonal antibodies, and small molecules, together have the potential to drive the existing market along with securing a significant market share upon introduction of new entrants to the CHF treatment landscape. LAS VEGAS, Jan. 22, 2025 /PRNewswire/ -- DelveInsight's Chronic Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, chronic heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Chronic Heart Failure Market Report According to DelveInsight's analysis, the market size for chronic heart failure was found to be approximately USD 5.5 billion in the US in 2023. Among the 7MM, the US contributed the largest market share of the total CHF market size and will continue to experience a steep rise in the market size throughout the forecast period. As per DelveInsight's estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20 million in 2023. Heart failure with preserved ejection fraction (HFpEF) contributed to most of the cases. Within class-specific diagnosed prevalence of Heart failure, NYHA class II and class III contribute the maximum. Established chronic heart failure companies with approved therapies in the market are Novartis, Otsuka, Boehringer Ingelheim/Eli Lilly, Bayer/Merck, Amgen/Servier, scPharmaceuticals, and Lexicon Pharmaceuticals/Viatris. In addition, Daiichi Sankyo and American Regent are targeting adult patients with heart failure who are iron deficient. Among all the approved therapies, Novartis and Otsuka's Entresto, approved since 2015 in the US, is still the leading therapy generating more than USD 4 billion in the 7MM in 2023. Among, Eli Lilly's Jardiance and AstraZeneca's Farxiga, both SGLT2 inhibitors, Farxiga is the leading prescribed SGLT2 inhibitor globally by volume Leading chronic heart failure companies developing emerging therapies, such as Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others are developing novel chronic heart failure drugs that can be available in the chronic heart failure market in the coming years. The promising chronic heart failure therapies in the pipeline include Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-740, HU6, and others. In October 2024, Viatris entered into an exclusive licensing agreement with Lexicon Pharmaceuticals for INPEFA (sotagliflozin) in all markets outside of the US and EU. In September 2024, Bayer presented the late-breaking data of Phase III FINE-HEART findings of KERENDIA (finerenone) during a Hot Line session at the European Society of Cardiology (ESC) Congress 2024. In May 2024, Eli Lilly and Company committed an additional USD 5.3 billion manufacturing investment in the company's newest Indiana site to boost API production for tirzepatide and pipeline medicines. AstraZeneca expects the data of the Phase III BalanceD-HF trial of balcinrenone (AZD9977) + dapagliflozin for heart failure in 2025. Discover which therapies are expected to grab the major chronic heart failure market share @ Chronic Heart Failure Market Report Chronic Heart Failure Overview Chronic heart failure is a long-term condition in which the heart's ability to pump blood efficiently is reduced, leading to inadequate circulation of oxygen and nutrients to meet the body's needs. The primary causes of CHF include coronary artery disease, high blood pressure, diabetes, cardiomyopathy, valvular heart disease, and previous heart attacks. Lifestyle factors like obesity, smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to its development. The symptoms of CHF vary in severity and may include persistent fatigue, shortness of breath, swelling in the legs, ankles, or abdomen, rapid or irregular heartbeat, and difficulty exercising. Advanced cases can lead to severe fluid retention, wheezing, and an inability to carry out daily activities. Diagnosis typically involves a comprehensive medical history review and a physical examination, followed by tests like an ECG to assess heart rhythm, echocardiography to evaluate heart structure and function, blood tests, chest X-rays, and stress tests. Early diagnosis and management are crucial to improving quality of life and preventing complications. Chronic Heart Failure Epidemiology Segmentation The chronic heart failure epidemiology section provides insights into the historical and current chronic heart failure patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The chronic heart failure market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Heart Failure Gender-specific Cases of Heart Failure Ejection Fraction-specific Cases of Heart Failure New York Heart Association (NYHA) Class-specific Cases of Heart Failure Type-specific Cases of Heart Failure Age-specific Cases of Heart Failure Chronic Heart Failure Treatment Market Current treatments for heart failure primarily rely on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics. Additional therapies, such as aldosterone antagonists, amiodarone, antiplatelets, anticoagulants, calcium channel blockers, and nitrates, are also utilized in managing the condition. Most treatment regimens involve a combination of therapies, with beta-blockers being among the most commonly prescribed. Among the approved treatments, Novartis' ENTRESTO has emerged as a leading drug in the congestive heart failure market. Initially slow to gain traction, ENTRESTO has become one of Novartis' key growth drivers, with revenue expected to increase in the coming years. Following its approval for use in patients with preserved ejection fraction, ENTRESTO's market presence has grown significantly. However, ENTRESTO faces growing competition. The entry of new drugs, including SGLT2 inhibitors (such as FARXIGA and JARDIANCE) and VERQUVO, poses a challenge to ENTRESTO's dominance. Additionally, Novartis is set to lose ENTRESTO's exclusivity in the United States in 2025, raising the risk of generic competition. The company is actively engaged in several patent lawsuits to protect its position. SGLT2 inhibitors have also gained a foothold in the CHF market. Although FARXIGA and JARDIANCE are established drugs, they are relatively new in this therapeutic area. The outlook for SGLT2 inhibitors in heart failure is promising, but AstraZeneca and Lilly/Boehringer will have limited time to solidify their positions, as FARXIGA's US patent expires in 2025 and JARDIANCE's in 2028. The recently approved SGLT2 inhibitor sotagliflozin may face challenges in capturing market share from these established treatments. To know more about chronic heart failure treatment guidelines, visit @ Chronic Heart Failure Management Chronic Heart Failure Pipeline Therapies and Key Companies Omecamtiv Mecarbil: Cytokinetics KERENDIA (finerenone): Bayer Tirzepatide (LY3298176): Eli Lilly and Company CardiAMP Cell Therapy: BioCardia Ziltivekimab (NN6018): Novo Nordisk REVASCOR (rexlemestrocel-L): Mesoblast Levosimendan (TNX-103): Tenax Therapeutics Semaglutide: Novo Nordisk Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca Mitiperstat (AZD4831): AstraZeneca Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb Lenrispodun (ITI - 214): Intra-Cellular Therapies CRD-740: Cardurion Pharmaceuticals HU6: Rivus Pharmaceuticals Discover more about chronic heart failure drugs in development @ Chronic Heart Failure Clinical Trials Chronic Heart Failure Market Dynamics The chronic heart failure market dynamics are expected to change in the coming years. An increasing prevalence of cardiovascular diseases, fueled by aging populations and lifestyle-related risk factors such as obesity, hypertension, and diabetes, has significantly raised the demand for effective CHF treatments. Advances in medical technology, including innovative drug therapies, cardiac devices, and regenerative medicine, are expanding treatment options and improving patient outcomes. Growing awareness about heart health and early diagnosis, supported by government and non-government initiatives, is also boosting market expansion. Additionally, the rising focus on personalized medicine and the development of therapies targeting the underlying molecular mechanisms of CHF are creating lucrative opportunities. The increasing healthcare expenditure and the availability of reimbursement policies in developed and emerging economies further bolster the market's growth trajectory. Furthermore, potential therapies are being investigated for the treatment of chronic heart failure, and it is safe to predict that the treatment space will significantly impact the chronic heart failure market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the chronic heart failure market in the 7MM. However several factors may impede the growth of the chronic heart failure market. A key challenge is the underdiagnosis and delayed recognition of CHF due to overlapping symptoms with other conditions and the lack of widespread access to advanced diagnostic tools in many regions. Economic constraints, particularly in low- and middle-income countries, limit patient access to costly therapies, including advanced drugs and devices. Additionally, adherence to treatment regimens remains low due to the complexity of management protocols and the long-term nature of care, leading to suboptimal outcomes. Regulatory hurdles and lengthy approval processes for novel therapies further impede the introduction of innovative treatments. Finally, a limited understanding among general practitioners about newer guidelines and therapies reduces the referral rates to specialists, creating gaps in patient care. Addressing these barriers requires concerted efforts in education, affordability, and healthcare infrastructure. Scope of the Chronic Heart Failure Market Report Therapeutic Assessment: Chronic Heart Failure current marketed and emerging therapies Chronic Heart Failure Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Heart Failure Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market Access and Reimbursement Download the report to understand which factors are driving chronic heart failure market trends @ Chronic Heart Failure Market Trends Table of Contents Related Reports Chronic Heart Failure Epidemiology Forecast Chronic Heart Failure Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic heart failure epidemiology trends. Chronic Heart Failure Pipeline Chronic Heart Failure Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHF companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, among others. Acute Coronary Syndrome Market Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ACS companies, including Novartis, Boehringer Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra , among others. Acute Coronary Syndrome Pipeline Acute Coronary Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute coronary syndrome companies, including Janssen Research & Development, LLC, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准引进/卖出

2025-01-22

·赛柏蓝

25省明确药事会召开时间！（附名单）

作者 | 颜色来源 | 赛柏蓝 01 26省明确药事会召开时间 31省双通道药品目录发布据赛柏蓝不完全统计，截至目前，已经有26地明确召开药事会：（1）1个月内召开药事会（4地）：上海、浙江、江苏、天津；（2）2025年2月底前召开药事会（21地）：安徽、湖南、北京、广东、新疆、宁夏、青海、甘肃、陕西、贵州、四川、重庆、海南、河南、山东、黑龙江、吉林、辽宁、内蒙古、湖北、西藏。注：完整名单见文末国谈药品进院情况一直是业内关注的重点，国家医保局通过及时召开药事会、建立完善谈判药品“双通道”保障机制等保障国谈药品落地。日前，国家医保局、人力资源社会保障部发布《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》的通知提到，积极推进新增药品进院。即医保定点医疗机构、工伤保险协议医疗机构和工伤康复协议机构原则上应于2025年2月底前召开药事会，根据《2024年药品目录》及时调整本机构用药目录，保证临床诊疗需求和参保患者合理用药权益。不得以医保总额限制、医疗机构用药目录数量、药占比为由影响药品进院。与去年相比，今年目前公布召开药事会的省份相较于往年均有所提前，药事会加速召开，国谈药品有望更快进院。从地方来看，2024年浙江省医保局已经公布了4次三级医疗机构国谈药品配备情况，部分国谈药品的进院数量排名发生了变化。 02 浙江国谈药品三级医疗机构进院情况公布 Top 10生变 1月17日，浙江省医保局发布全省三级医疗机构谈判药品配备情况一览表（2024年第四季度），国谈药品进院数量、各地市配备情况公布。赛柏蓝对比浙江省2024年四季度国谈药品的进院数量排名，沙库巴曲缬沙坦钠片、醋酸戈舍瑞林缓释植入剂、司美格鲁肽注射液一直保持在2024年浙江省三级医疗机构谈判药品配备情况前三名。并且，沙库巴曲缬沙坦钠片每季度进院数量递增，1-4季度分别是151、153、154、156。与第三季度相比，不少药品的排名发生了明显的变化。第四季度的Top 4-10药品分别是德谷门冬双胰岛素注射液、布地格福吸入气雾剂、丁苯酞氯化钠注射液、丁苯酞软胶囊、注射用阿替普酶、重组人血小板生成素注射液、百令胶囊。具体如下：浙江省一到四季度的药品进院超过100家的品种数呈较大幅度增长，第一季度进院超过100家药品有17个，第二季度进院超过100家药品有19个、第三季度进院超过100家药品有23个、第四季度进院超过100家药品有24个。一直处于进院Top 1的沙库巴曲缬沙坦钠片，是由诺华研发的全球首款血管紧张素受体-脑啡肽酶抑制剂（ARNI），用于射血分数降低的慢性心力衰竭和原发性高血压。米内网数据显示，2023年中国公立医疗机构终端沙库巴曲缬沙坦钠片销售额大涨62.80%，突破30亿元。 Top 2的醋酸戈舍瑞林缓释植入剂，用于前列腺、乳腺癌等疾病治疗，2021年在中国公立医疗机构终端的销售额超过30亿元。 Top 3的司美格鲁肽注射液是明星药物，2023年在中国三大终端六大市场，原研的司美格鲁肽注射液（生物制品）销售额超过54亿元。附： 1.各地召开“药事会”时限及具体要求 2.双通道、单独支付、特殊药品目录等相关信息制图：颜色制图：陈芋 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

2025-01-21

·药闻康策

这104个产品或满足第十一批国采条件

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策 1月17日上午，国家医保局召开“保障人民健康赋能经济发展”新闻发布会，总结了四同药品价格治理、医保基金安全监管等多项工作进展及成效，也对今年将要展开的国家集采、国家医保目录调整等工作作出规划。国家医保局表示，2025年上半年将开展第11批药品集采，下半年将开展第6批高值医用耗材集采，并适时启动新批次药品集采。近年来，国采门槛逐步提高，到第十批时，各品种的竞争格局≥7家，若第十一批依然延续这一标准，据本号梳理，目前综合过评满七家的产品已超过104个，包括沙库巴曲缬沙坦钠片、注射用头孢唑肟钠、二羟丙茶碱注射液、吸入用乙酰半胱氨酸溶液等多个大品种。（说明:过评竞争格局≥7家的非国产品种，数据更新至1月20日，竞争格局符合条件不一定会纳入国家集采，一切信息以官网为准！) (来源:药通社）有需要《104个产品或满足第十一批国采条件》完整Excel电子版，请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购

100 项与沙库巴曲缬沙坦钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C09DX04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
原发性高血压	中国	Novartis Pharma Schweiz AG	2021-05-24
高血压	日本	Novartis Pharma KK	2020-06-29
左心室收缩功能障碍	美国	Novartis Pharmaceuticals Corp.	2019-10-01
射血分数降低的慢性心力衰竭	欧盟	Novartis Europharm Ltd.	2015-11-19
射血分数降低的慢性心力衰竭	冰岛	Novartis Europharm Ltd.	2015-11-19
射血分数降低的慢性心力衰竭	列支敦士登	Novartis Europharm Ltd.	2015-11-19
射血分数降低的慢性心力衰竭	挪威	Novartis Europharm Ltd.	2015-11-19
心脏衰竭	瑞士	Novartis AG	2015-09-17
慢性心力衰竭	美国	Novartis Pharmaceuticals Corp.	2015-07-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床3期	韩国	Chong Kun Dang Pharmaceutical Corp.	2024-10-14
心肌梗塞后综合征	临床3期	-	Novartis Pharmaceuticals Corp.	2021-05-26
胎儿水肿	临床3期	日本	Novartis Pharmaceuticals Corp.	2019-05-07
勃起功能障碍	临床3期	德国	Novartis Pharmaceuticals Corp.	2019-04-16
收缩性心力衰竭	临床3期	德国	Novartis Pharmaceuticals Corp.	2019-04-16
急性心肌梗塞	临床3期	美国	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	中国	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2016-12-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03168568 (VASCEND, Pubmed \| JACC Adv)	临床4期	心脏衰竭	79	Sacubitril/Valsartan	鹽壓艱製製繭製膚鑰簾(鑰選壓鹽憲鹹積範鏇範) = 鑰憲獵壓鬱觸糧襯廠淵憲繭網蓋選鑰壓構鹹築 (鏇蓋網廠廠範餘鹹糧觸, 3.9) 更多	不佳	2024-12-01
				Valsartan	鹽壓艱製製繭製膚鑰簾(鑰選壓鹽憲鹹積範鏇範) = 觸簾憲製網願壓糧廠窪憲繭網蓋選鑰壓構鹹築 (鏇蓋網廠廠範餘鹹糧觸, 2.8) 更多
NCT01035255 (PARADIGM-HF, Pubmed \| Eur J Heart Fail)	临床3期	射血分数降低的心力衰竭 \| 慢性心力衰竭	8,399	Beta-blocker	鏇壓鬱構鏇窪製範夢壓(衊蓋構糧窪觸構築獵繭): HR = 0.47 (95% CI, 0.32 ~ 0.69) 更多	积极	2024-11-19
				No Beta-blocker
NCT02678312 (PANORAMA-HF, Pubmed \| Circulation) 人工标引	临床2/3期	心脏衰竭	375	Sacubitril/Valsartan	鑰積艱選衊鑰積鹽選選(餘顧鬱鑰鏇選夢齋壓簾): OR = 0.91 (95% CI, 0.72 ~ 1.14), P-Value = 0.42 更多	不佳	2024-09-25
				Enalapril
NCT01920711 (PARAGON-HF, Pubmed \| Eur J Heart Fail)	临床3期	心脏衰竭	4,795	Sacubitril/valsartan	鏇獵獵艱廠觸夢選鏇艱(醖繭膚壓鹽鏇範獵範構) = 憲範構餘蓋鑰淵鏇壓壓觸齋觸構製網觸範艱醖 (鹽構憲糧網憲窪鏇簾鹹, 0.0 ~ 0.2) 更多	积极	2024-09-01
				Valsartan	鹽窪膚醖醖願醖繭鹽醖(遞簾獵鑰齋範餘鑰築鏇) = 顧積積鹹鏇獵壓膚鬱廠觸壓簾衊鑰鑰選襯製窪 (艱鹽衊夢鹽鏇積壓鬱餘 ) 更多
ESC2024	N/A	心脏衰竭	-	Sacubitril/Valsartan (Patients aged below 80 years)	鑰顧遞窪鹽鑰構製憲網(夢齋鬱網襯鬱淵範範鹽) = 淵構廠觸網鏇窪糧鹹鬱觸憲鬱鹽鏇衊鑰鬱淵艱 (艱鹽鏇鹹艱蓋鑰艱糧構 )	-	2024-08-31
				Sacubitril/Valsartan (Patients aged above 80 years)	鑰顧遞窪鹽鑰構製憲網(夢齋鬱網襯鬱淵範範鹽) = 製窪艱夢襯願網廠遞選觸憲鬱鹽鏇衊鑰鬱淵艱 (艱鹽鏇鹹艱蓋鑰艱糧構 )
ESC2024	N/A	-	24	sacubitril/valsartan (Control)	鹹構糧製餘鹹鬱築壓憲(顧艱膚窪鹽鬱獵網構範) = 觸選鏇積窪蓋築遞顧衊衊選齋鹹糧鹽窪簾齋鏇 (顧顧鹽鏇範簾製觸觸範 )	不佳	2024-08-31
				Sacubitril/Valsartan	鹹構糧製餘鹹鬱築壓憲(顧艱膚窪鹽鬱獵網構範) = 醖選簾選遞積壓襯淵艱衊選齋鹹糧鹽窪簾齋鏇 (顧顧鹽鏇範簾製觸觸範 )
ESC2024	N/A	心脏病	-	ARNI Sacubitril/Valsartan	淵觸顧遞鹽願鏇淵獵構(遞齋獵選淵膚遞齋鑰獵) = 顧鏇顧築鑰簾夢醖憲夢網顧鏇遞遞艱憲壓遞襯 (網廠鹹範鹽製淵艱糧壓, 806 ~ 4330)	-	2024-08-31
ESC2024	N/A	心脏衰竭	-	sacubitril-valsartan (Patients <75 years old)	築築夢簾築構鑰觸選遞(鏇淵夢簾製鏇蓋遞衊壓) = very few patients were hospitalized for reasons related to angioedema, 16/44,743 in ≥75 y patients and 26/60,167 in those <75 y 鏇鏇醖窪繭夢選憲鏇廠 (蓋願糧夢積糧膚顧蓋憲 )	-	2024-08-30
				sacubitril-valsartan (Patients ≥75 years old)
NCT02884206 (PERSPECTIVE, CTgov)	临床3期	慢性心力衰竭	592	Placebo of Valsartan+LCZ696 (LCZ696 200 mg Bid)	艱簾網窪鑰憲積鹹鹹顧(鬱壓糧選構獵鬱觸糧糧) = 夢齋構鑰獵觸繭選衊糧願夢築窪淵鏇鏇糧淵夢 (觸鏇齋艱鹹觸蓋衊齋艱, 鬱構遞壓鏇積膚積憲淵 ~ 鬱網艱網鏇範積積膚艱) 更多	-	2024-08-06
				Placebo of LCZ696+Valsartan (Valsartan 160 mg Bid)	艱簾網窪鑰憲積鹹鹹顧(鬱壓糧選構獵鬱觸糧糧) = 鹽鹽構蓋鏇獵網鑰襯夢願夢築窪淵鏇鏇糧淵夢 (觸鏇齋艱鹹觸蓋衊齋艱, 製廠網艱製膚鹽壓窪簾 ~ 願築獵鑰襯淵艱憲鏇願) 更多
NCT03988634 (PARAGLIDE-HF, CTgov)	临床3期	射血分数保留型心力衰竭	467	valsartan matching placebo+sacubitril/valsartan (Sacubitril/Valsartan (LCZ696))	範鏇蓋蓋製齋廠觸蓋膚(廠遞艱鏇淵遞簾鏇憲膚) = 憲願簾鹹夢鑰鬱窪繭鏇壓蓋蓋糧顧顧鏇衊選糧 (繭觸獵夢鑰蓋繭鏇繭壓, 壓膚願構製廠積夢窪淵 ~ 糧積範蓋廠範襯鹹築構) 更多	-	2024-07-29
				sacubitril/valsartan matching placebo+valsartan (Valsartan)	範鏇蓋蓋製齋廠觸蓋膚(廠遞艱鏇淵遞簾鏇憲膚) = 艱糧遞觸醖齋構願積憲壓蓋蓋糧顧顧鏇衊選糧 (繭觸獵夢鑰蓋繭鏇繭壓, 獵鏇選鬱鹹製壓製糧膚 ~ 願製觸選夢襯襯窪夢壓) 更多